Anbio Biotechnology - Class A

Research Anbio Biotechnology - Class A (NNNN) on Bullrun: market cap USD 594.73M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNNNN
• ExchangeNASDAQ
• CountryGermany
• SectorHealthcare
• IndustryMedical Instruments & Supplies
• CurrencyUSD
• Market capUSD 594.73M
• Financial periodFY2025
• RevenueUSD 8.65M
• Revenue growth5.6%
• Net incomeUSD 6.40M
• Gross margin87.2%

Valuation Snapshot

latest market cap is USD 594.73M.

About Anbio Biotechnology - Class A

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets.

Frequently asked questions

What is Anbio Biotechnology - Class A's market cap?

Anbio Biotechnology - Class A's market capitalization is USD 594.73M.

What does Anbio Biotechnology - Class A do?

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.